Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 184.60
Bid: 184.20
Ask: 185.20
Change: -3.20 (-1.70%)
Spread: 1.00 (0.543%)
Open: 190.00
High: 190.00
Low: 184.60
Prev. Close: 187.80
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director Declaration

10 Nov 2022 17:00

RNS Number : 0398G
PureTech Health PLC
10 November 2022
 

10 November 2022

 PureTech Health plc

 

Director Declaration

 

Pursuant to Listing Rule 9.6.14(2), PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") notes that Christopher Viehbacher, a Non-Executive Director and Chair of the Company's Board, has been appointed as President and Chief Executive Officer and a member of the Board of Biogen Inc. (Nasdaq: BIIB) with effect from November 14, 2022. 

 

For further information please contact:

Bharatt Chowrira, PhD, JD, President and Chief Business, Finance and Operating Officer, member of the Board of Directors and Company Secretary: +1 617 482 2333

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNEAKFEFFPAFFA
Date   Source Headline
15th Apr 20197:00 amRNSGelesis Receives FDA Clearance for First Product
11th Apr 20191:00 pmRNSAkili Makes CFO & General Counsel Appointments
11th Apr 20197:05 amRNSGelesis Presents Data on Effects of High-Fat Diet
11th Apr 20197:00 amRNSSonde Completes $16M Series A Financing Round
2nd Apr 20197:00 amRNSPRTC Presents Immuno-Oncology Programmes at AACR
1st Apr 201912:05 pmRNSKaruna expands Series B financing to $80 million
25th Mar 20196:00 pmRNSGelesis New Clinical Data on Impact of Gelesis100
25th Mar 20196:00 pmRNSGelesis Preclinical Data on Restoring Gut Barrier
21st Mar 20197:00 amRNSGelesis to Present at Endocrine Society Annual Mtg
18th Mar 20197:00 amRNSKaruna Announces $68 Million Series B Financing
15th Mar 20197:00 amRNSNotice of Results
7th Mar 20197:00 amRNSAkili & Shionogi Deal in Taiwan/Japan $20M upfront
5th Mar 20197:00 amRNSKaruna Appoints Chief Financial Officer
22nd Feb 20194:41 pmRNSSecond Price Monitoring Extn
22nd Feb 20194:36 pmRNSPrice Monitoring Extension
21st Feb 20197:00 amRNSPRTC to Present at Two US Investor Conferences
15th Feb 20194:41 pmRNSSecond Price Monitoring Extn
15th Feb 20194:35 pmRNSPrice Monitoring Extension
14th Feb 20197:00 amRNSVor Raises $42M to Advance Leukaemia Treatment
28th Jan 20197:00 amRNSAlivio Partners to Advance Non-opioid Pain Therapy
23rd Jan 20196:08 pmRNSVedanta Immuno-oncology Candidate Published
2nd Jan 20197:00 amRNSTotal Voting Rights
28th Dec 201812:07 pmRNSSecond Price Monitoring Extn
28th Dec 201812:02 pmRNSPrice Monitoring Extension
24th Dec 20187:00 amRNSVedanta Biosciences Raise $27M Series C Financing
17th Dec 20187:00 amRNSVedanta Initiates Phase 2 Study for Lead Candidate
10th Dec 20187:00 amRNSVedanta & BMS Immuno-Oncology Collaboration
28th Nov 20187:00 amRNSVor Granted First-in-class Immuno-oncology Patent
27th Nov 20187:00 amRNSJanssen/Vedanta Phase 1 in IBD & $12M Milestone
26th Nov 20184:40 pmRNSSecond Price Monitoring Extn
26th Nov 20184:35 pmRNSPrice Monitoring Extension
22nd Nov 201812:07 pmRNSSecond Price Monitoring Extn
22nd Nov 201812:02 pmRNSPrice Monitoring Extension
16th Nov 201812:07 pmRNSSecond Price Monitoring Extn
16th Nov 201812:02 pmRNSPrice Monitoring Extension
14th Nov 201812:07 pmRNSSecond Price Monitoring Extn
14th Nov 201812:02 pmRNSPrice Monitoring Extension
13th Nov 201811:05 amRNSFull Gelesis Data Published in the Journal Obesity
7th Nov 20187:00 amRNSPRTC to Present at Jefferies 2018 in London
6th Nov 20181:00 pmRNSVedanta Presents Data on Immuno-Oncology Candidate
5th Nov 20187:00 amRNSGelesis to Present Full Data for Lead Candidate
31st Oct 201812:07 pmRNSSecond Price Monitoring Extn
31st Oct 201812:02 pmRNSPrice Monitoring Extension
17th Oct 20187:00 amRNSKaruna Adds Sage Therapeutics CEO to Board
16th Oct 201812:20 pmRNSresTORbio Announces Additional Positive Ph 2b Data
15th Oct 20187:00 amRNSKaruna Initiates Phase 2 Study in Schizophrenia
4th Oct 20187:00 amRNSVedanta Announces Successful Ph1 Clinical Results
17th Sep 20184:15 pmRNSBrain Lymphatics Published in Nature Neuroscience
12th Sep 201812:00 pmRNSAkili Exclusively Licenses New Digital Technology
12th Sep 20187:00 amRNSAlivio Awarded $3.3M Grant from US Dept of Defense

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.